VELCADE

The actual benefit of VELCADE is substantial in the induction treatment of patients with newly diagnosed multiple myeloma who are eligible for haematopoietic stem cell transplantation (HSCT).

In combination with dexamethasone or with dexamethasone and thalidomide, VELCADE provides a moderate improvement in actual benefit (level III) in terms of efficacy in the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with HSCT.